Activation of the mTOR signaling pathway in breast cancer MCF‑7 cells by a peptide derived from Porphyra yezoensis

Park,Su-Jin; Ryu,Jina; Kim,In-Hye; Choi,Youn-Hee; Nam,Taek-Jeong

doi:10.3892/or.2014.3557

Activation of the mTOR signaling pathway in breast cancer MCF‑7 cells by a peptide derived from Porphyra yezoensis

Authors:
- Su-Jin Park
- Jina Ryu
- In-Hye Kim
- Youn-Hee Choi
- Taek-Jeong Nam
View Affiliations

Affiliations: Department of Food and Science, Pukyong National University, Busan 608-737, Republic of Korea, Institute of Fisheries Science, Pukyong National University, Busan 619-911, Republic of Korea
Published online on: October 20, 2014 https://doi.org/10.3892/or.2014.3557
Pages: 19-24
Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Seaweeds have beneficial nutritional and medicinal properties. Several studies have examined the polysaccharides found in the extracts of Porphyra yezoensis (PPY), although the effects of particular proteins have not been reported, and peptides from the marine alga PPY function in antitumor cell signaling, although the precise mechanism is not well understood. Apoptosis plays an important role in cell death, which affects cell proliferation. Generally, regulation of apoptosis requires participation of the p53 and Bcl-2 family by the mammalian target of rapamycin (mTOR) pathway, which is activated in a variety of malignant cancers. Autophagy is another signaling pathway that leads to degradation of cellular components by lysosomal activity, and the relationship between autophagy and cancer has been of interest for several years. The present study investigated mTOR pathway activation in MCF-7 cells treated with 500 ng PPY for 24 h by assessing LC3 as a monitor of autophagy. We observed that the p53/NF-κB and mTOR pathways were affected by PPY, which contributes to our understanding of the functional relationship between the Bcl-2 family and mTOR under apoptotic conditions in MCF-7 cells.

View Figures

View References

1	American Cancer Society, Cancer Facts and Figures. American Cancer Society; Atlanta, GA: 2009
2	He X, Wang Y, Zhu J, Orloff M and Eng C: Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett. 301:168–176. 2011. View Article : Google Scholar
3	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
4	Pattingre S, Espert L, Biard-Piechaczyk M and Codogno P: Regulation of macroautophagy by mTOR and Beclin1 complexes. Biochimie. 90:313–323. 2008. View Article : Google Scholar
5	Bärlund M, Forozan F, Kononen J, et al: Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 92:1252–1259. 2000. View Article : Google Scholar : PubMed/NCBI
6	Sekulic A, Hudson CC, Homme JL, et al: A direct linkage between the phosphosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60:3504–3513. 2000.
7	Lmoki K, Li Y, Zhu T, Wu J and Guan KL: TSC2 is phosphorylated and inhibited by AKT and suppresses mTOR signaling. Nat Cell Biol. 4:648–657. 2002. View Article : Google Scholar
8	Chung J, Kuo CJ, Crabtree GR and Bieris J: Rapamycin FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 69:1227–1236. 1992. View Article : Google Scholar : PubMed/NCBI
9	Holland EC, Sonenberg N, Pandolfi PP and Thomas G: Signaling control of mRNA translation in cancer pathogenesis. Oncogene. 23:3138–3144. 2004. View Article : Google Scholar : PubMed/NCBI
10	Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
11	Antonsson B and Martinou JC: The Bcl-2 protein family. Exp Cell Res. 256:50–57. 2000. View Article : Google Scholar : PubMed/NCBI
12	Yin XM, Oltvai ZN and Korsmeyer SJ: BH1 and BH2 domain of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 369:321–323. 1994. View Article : Google Scholar : PubMed/NCBI
13	Reed JC: Bcl-2 family protein: regulators of apoptosis and chemo-resistance in hematologic malignancies. Semin Hematol. 34:9–19. 1997.PubMed/NCBI
14	Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
15	Malaguarnera L: Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev. 23:367–387. 2004. View Article : Google Scholar : PubMed/NCBI
16	Khwaja A: Akt is more than just a Bad kinase. Nature. 401:33–34. 1999. View Article : Google Scholar : PubMed/NCBI
17	McCormick F: Cancer: survival pathways meet their end. Nature. 428:267–269. 2004. View Article : Google Scholar : PubMed/NCBI
18	Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2:301–310. 2002. View Article : Google Scholar : PubMed/NCBI
19	Steele RJ and Lane DP: p53 in cancer: a paradigm for modern management of cancer. Surgeon. 3:197–205. 2005. View Article : Google Scholar : PubMed/NCBI
20	Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Downregulation of Bcl-2 by p53 in breast cancer cells. Cancer Res. 54:2095–2097. 1994.PubMed/NCBI
21	Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI
22	Bentires-Alj M, Dejardin E, Viatour P, Van Lint C, Froesch B, Reed JC, Mervile MP and Bours V: Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene. 20:2805–2813. 2001. View Article : Google Scholar : PubMed/NCBI
23	Heckman CA, Mehew JW and Boxer LM: NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene. 21:3898–3908. 2002. View Article : Google Scholar : PubMed/NCBI
24	Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh h and Troxel A: Promotion of tumorigenesis by heterozygous disruption of the beclin1 autophagy gene. J Clin Invest. 112:1809–1820. 2003. View Article : Google Scholar : PubMed/NCBI
25	Matshushita M, Suzuki NN, Obara K, Fujioka Y, Ohsumi Y and Inagaki F: Structure of Atg5.Atg16, a complex essential for autophagy. J Biol Chem. 282:6763–6772. 2007. View Article : Google Scholar
26	Park SJ, Ryu J, Kim IH, Choi YH and Nam TJ: Induction of apoptosis by a peptide from Porphyra yezoensis: regulation of the insulin-like growth factor I receptor signaling pathway in MCF-7 cells. Int J Oncol. 45:1011–1016. 2014.PubMed/NCBI
27	Yuan TL and Cantley LC: PI3K pathway alterations in cancer: variations on theme. Oncogene. 27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
28	Xu X, Sakon M, Nagano H, Hiraoka N, et al: Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep. 11:25–32. 2004.
29	Faivre S, Kroener G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 5:671–688. 2006. View Article : Google Scholar : PubMed/NCBI
30	Dann SG and Thomas G: The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett. 580:2821–2829. 2006. View Article : Google Scholar : PubMed/NCBI
31	Akar U, Ozpolat B, Mehta K, et al: Targeting p70S6k prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 9:1180–1187. 2010. View Article : Google Scholar : PubMed/NCBI
32	Fesus L and Szondy Z: Transglutaminase 2 in the balance of cell death and survival. FEBS Lett. 579:3297–3302. 2005. View Article : Google Scholar : PubMed/NCBI
33	Herman JF, Mangala LS and Mehta K: Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene. 25:3049–3058. 2006. View Article : Google Scholar : PubMed/NCBI
34	Fesus L and Piacentini M: Transglutaminase 2: an enigmatic enezyme with diverse function. Trends Biochem Sci. 27:534–539. 2002. View Article : Google Scholar : PubMed/NCBI
35	Malek R, Borrowicz KK, Jargiełło M and Czuczwar SJ: Role of nuclear factor kappaB in the in the central nervous system. Pharmacological Rep. 59:25–33. 2007.
36	Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D and Reed JC: Bax directly induced release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA. 95:4997–5002. 1998. View Article : Google Scholar
37	Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
38	Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29:15–18. 2002. View Article : Google Scholar
39	Zhang DM, Liu JS, Deng LJ, et al: Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 34:1331–1342. 2013. View Article : Google Scholar : PubMed/NCBI
40	Eskelinen FL: Maturation of autophagic vacuoles in Mammalian cells. Autophagy. 1:1–10. 2005. View Article : Google Scholar
41	Jing Ji and Zheng PS: Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol. 117:103–108. 2010. View Article : Google Scholar
42	Cho MY, Park SY, Park S, Lee YR, Han GD and Kim JA: Geranyl derivative of phloroacetophenone induces cancer cell-specific apoptosis through Bax-mediated mitochondrial pathway in MCF-7 human breast cancer cells. Biol Pharm Bull. 35:98–104. 2012. View Article : Google Scholar : PubMed/NCBI
43	Lee KB, Byun HJ, Park SH, Park CY, Lee SH and Rho SB: CYR61 controls p53 and NF-κB expression through PI3K/AKT/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett. 315:86–95. 2012. View Article : Google Scholar
44	Klionsky DJ: The molecular machinery of autophagy: unanswered questions. J Cell Sci. 118:7–18. 2005. View Article : Google Scholar
45	Dumont FJ and Su Q: Mechanism of action of the immunosuppressant rapamycin. Life Sci. 58:373–395. 1996. View Article : Google Scholar : PubMed/NCBI
46	Windecker S, Roffi M and Meier B: Sirolimus eluting stent: a new era in interventional cardiology? Curr Pharm Des. 9:1077–1094. 2003. View Article : Google Scholar : PubMed/NCBI
47	Gao XM, Wong G, Wang B, et al: Inhibition of mTOR reduces chronic pressure overload cardiac hypertrophy and fibrosis. J Hypertens. 24:1663–1670. 2006. View Article : Google Scholar : PubMed/NCBI
48	Simler NR, Howell DC, Marshall RP, et al: The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rat. Eur Respir J. 19:1124–1127. 2002. View Article : Google Scholar : PubMed/NCBI
49	Achenbach TV, Barrow RK and Heerneier K: Oligonucleotide-based knockdown technologies: antisense versus RNA interference. Chembiochem. 4:928–935. 2003. View Article : Google Scholar : PubMed/NCBI
50	Burnet PE, Barrow RK, Cohen NA, Snyder SH and Sabatini DM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Nat Acad Sci USA. 95:1432–1437. 1998. View Article : Google Scholar